A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

Lead Sponsor

Ferring Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•have documented evidence of rCDI (≥1 recurrence after a primary CDI episode)
•be undergoing antibiotic treatment for the qualifying rCDI episode that was diagnosed by a stool test for the presence of toxigenic C. difficile or C. difficile toxin
•be eligible for FMT as judged by the investigator or current treatment guidelines for rCDI in the US
•be a candidate for colonoscopy as judged by the investigator

•Use or planned use of systemic antibiotics for an indication other than the qualifying rCDI episode.
•Current uncontrolled chronic diarrhea not related to CDI.
•Receipt of CDI vaccine or treatment with CDI monoclonal antibodies within the past 12 months before screening.
•Evidence of active, severe, or fulminant colitis, diagnosis of toxic megacolon or have a current colostomy or ileostomy

Related studies

NCT06237452 · Clostridium Difficile, Clostridium Difficile Infections, and more

NCT03617445 · Clostridium Difficile Infection Recurrence

NCT04317963 · Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence

NCT04891965 · Clostridium Difficile Infection Recurrence